Pardi et al. (2018) “Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses” Journal of Experimental Medicine.
DOI:10.1084/jem.20171450
News & Publications
Lutz et al. (2017) “Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines” NPJ Vaccines.
DOI:10.1038/s41541-017-0032-6
Thran et al. (2017) “mRNA mediates passive vaccination against infectious agents, toxins, and tumors” EMBO Molecular Medicine.
DOI:10.15252/emmm.201707678
Pardi et al. (2017) “Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge” Nature Communications.
DOI:10.1038/ncomms14630
Pardi et al. (2017) “Zika virus protection by a single low-dose nucleoside-modified mRNA Vaccination” Nature.
DOI:10.1038/nature21428
Pardi et al. (2015) “Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes” Journal of Controlled Release.
DOI:10.1016/j.jconrel.2015.08.007
Thess et al. (2015) “Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals” Molecular Therapy.
DOI:10.1038/mt.2015.103
Maier et al. (2013) “Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics” Molecular Therapy.
DOI:10.1038/mt.2013.124
Mui et al. (2013) “Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles” Molecular Therapy Nucleic Acids.
DOI:10.1038/mtna.2013.66
Jayaraman et al. (2012) “Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo” Angewandte Chemie.
DOI:10.1002/anie.201203263
Akinc et al. (2010) “Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms” Molecular Therapy.
DOI:10.1038/mt.2010.85
Semple et al. (2010) “Rational design of cationic lipids for siRNA delivery” Nature Biotechnology.
DOI:10.1038/nbt.1602